Onclive Team

Oncology continues to lead all therapeutic areas in drug development research, with nearly 5500 of more than 17,000 projects in the works.

Patients diagnosed with melanoma are typically affected psychologically. Researchers summarized health-related quality of life (HRQOL) during the 12-week ipilimumab induction period in previously treated patients diagnosed with advanced stage III or IV melanoma.

In each issue, Urologists in Cancer Care presents summaries of ongoing research relating to a variety of urologic cancers.

Combining two commonly used drugs for myeloproliferative neoplasms achieved what the individual drugs could not: a high response rate with few side effects.

Robot-assisted radical prostatectomy adoption into medical practice has been swift and encompassing, even as questions remain about its efficacy, added costs, and perioperative and longer-term outcomes versus alternatives.

Analysis of the cost-effectiveness of ipilimumab compared with best supportive care in previously treated patients with advanced (unresectable or metastatic) melanoma.

Although it is now standard practice to utilize the second-generation TKIs dasatinib or nilotinib in patients whose CML has recurred while taking imatinib treatment, published support for the economic value of this approach is lacking.

The novel immunotherapy talimogene laherparepvec has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma.

This year marks the 30th Annual Miami Breast Cancer Conference, a milestone for Daniel A. Osman, MD, and his wife Lois, who together launched the gathering in 1983 with fewer than 100 attendees and a focus on the then relatively new domain of lumpectomies in breast cancer treatment.

The 2013 Genitourinary Cancers Symposium was held at the Rosen Shingle Creek, Orlando, Florida, from February 14-16.

Several updates highlighted at the 2012 American Society of Hematology Annual Meeting as well as other developments.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide, in acute promyelocytic leukemia.

The 2013 Gastrointestinal Cancers Symposium was held at the Moscone West Building, San Francisco, CA, from January 24-26.

A panel of experts provides their thoughts on the USPSTF PSA screening recommendations, and how this widely publicized health message has impacted their urology practices.

Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.

Photos from the 35th annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 4-8, 2012.

For the past 10 years, Matthew J.C. Ellis, MB BChir, PhD, has focused his research on exploring the breast cancer genome in partnerships with academic and government-funded centers in the United States and the United Kingdom.

A data safety monitoring board (DSMB) has found that a phase III study of pomalidomide, an oral immunomodulatory agent, met its primary endpoint by demonstrating a significant improvement in progression-free survival for patients with multiple myeloma (MM).

A research team has discovered 12 genetic markers associated with the development of erectile dysfunction in prostate cancer patients treated with radiation.

Pertuzumab, a new HER2-positive breast cancer drug, is being launched at a 31% premium to the price of trastuzumab.

Medical homes are physician-led healthcare teams that coordinate care for patients and typically rely on electronic methods for record-keeping, care coordination, and data collection.

Urologists in Cancer Care presents summaries of ongoing research relating to a variety of urologic cancers.

The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.

National summit convened to reduce overuse of unnecessary procedures and treatments.

A thorough examination of emerging strategies for the treatment of breast cancer, as well as the clinical data underlying new and existing options, will form the cornerstone of the 9th Annual School of Breast Oncology.

The expansion of testing for genetic abnormalities in patients with advanced lung cancer is generating questions about which patients' tumors should be tested, how they should be tested, and whether they should be retested.

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Jeffrey S. Weber, MD, PhD, specializes in cancer immunotherapy and has been involved in numerous trials of clinical drug development, vaccines, and studies on autoimmunity and melanoma.

A whole-blood prognostic test based on gene-expression signatures may help predict risk for patients with castration-resistant prostate cancer.

Photos from the 2012 National Coalition of Oncology Nurse Navigators' (NCONN) annual conference that was held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, Tennessee.